Skip to content

Skip to secondary menu

Jehovah’s Witnesses


Hematology (Oncology)

Anemia Management

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B

Source‎: Source: Cochrane Database Syst Rev 2016;2:CD009624.

Indexed‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

The safety of intravenous iron preparations: systematic review and meta-analysis.

Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A.

Source‎: Mayo Clin Proc 2015;90(1):12-23.

Indexed‎: PubMed 25572192

DOI‎: 10.1016/j.mayocp.2014.10.007

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, D­íez-Campelo M, et al.

Source‎: Eur J Haematol 2015 Sep. [Epub ahead of print]

Indexed‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

What is the right balance between iron and erythropoiesis stimulating agents in chemotherapy induced anemia?

Auerbach M, Glaspy J.

Source‎: Eur J Clin Med Oncol 2009;1(1):1-6.

Indexed‎: ISSN 1759-8958

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Source‎: Ann Oncol 2013;24(2):475-82.

Indexed‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

Update on safety of ESAs in cancer-induced anemia.

Glaspy J.

Source‎: J Natl Compr Canc Netw 2012;10(5):659-66.

Indexed‎: PubMed 22570294

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Source‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Indexed‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.

Azzarà A, Carulli G, Galimberti S, Baratè C, Fazzi R, Cervetti G, Petrini M.

Source‎: Am J Hematol 2011;86(9):762-7.

Indexed‎: PubMed 21850658

DOI‎: 10.1002/ajh.22111

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Source‎: Cancer 2012;118(3):848-55.

Indexed‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

Management of anemia in cancer patients.

Calabrich A, Katz A.

Source‎: Future Oncol 2011;7(4):507-17.

Indexed‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Source‎: Support Care Cancer 2012;20(1):159-65.

Indexed‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy.

Crary SE, Hall K, Buchanan GR.

Source‎: Pediatr Blood Cancer 2011;56(4):615-9.

Indexed‎: PubMed 21298748

DOI‎: 10.1002/pbc.22930

Parenteral iron therapy in cancer-associated anemia.

Henry DH.

Source‎: Hematology Am Soc Hematol Educ Program 2010;2010:351-6.

Indexed‎: PubMed 21239818

DOI‎: 10.1182/asheducation-2010.1.351

Intravenous iron in oncology.

Auerbach M, Ballard H.

Source‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Indexed‎: PubMed 18597712

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.